Scarica l'app Stockscreener
0.74
0.68%
0.005
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
Avenue Therapeutics (NASDAQ:ATXI) vs. ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Analysis - Defense World
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com
Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times
Park Avenue Securities LLC Has $212,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - Defense World
United Therapeutics Corporation $UTHR Stake Lifted by Park Avenue Securities LLC - Defense World
2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - Defense World
Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment - Yahoo Finance
Postoperative Pain Management Market to Expand Significantly by 2032, States DelveInsight Report - openPR.com
SpringWorks Therapeutics Inc.’s volatility index tracking explainedEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Profit Summary & AI Optimized Trade Strategies - newser.com
Is TScan Therapeutics Inc. meeting your algorithmic filter criteria2025 Valuation Update & Safe Capital Growth Tips - newser.com
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol - IT Business Net
7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise
Coya Therapeutics to Participate at Upcoming September 2025 Investor Conferences - biospace.com
Coya Therapeutics to Participate at Upcoming September Investor Conferences - Stock Titan
How to escape a deep drawdown in Bicara Therapeutics Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser
FBIO In FocusWill CUTX-101 Make History As The First FDA-Approved Menkes Disease Therapy? - RTTNews
Plus Therapeutics Inc. stock trend forecastPortfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser
Abeona Therapeutics to expand in Midtown - NEO-Trans.blog
Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average PT from Analysts - MarketBeat
Has Anika Therapeutics Inc. formed a bullish divergenceJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks
North American Morning Briefing : Stock Futures -2- - MarketScreener
Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada
Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Postoperative Pain Management Market to Expand Significantly - openPR.com
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 BillionWSJ - The Wall Street Journal
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World
Yousif Capital Management LLC Has $1.99 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 156.3% in May - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
NBC Securities Inc. Takes $31,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
2.96%
0.09%
Capitalizzazione:
|
Volume (24 ore):